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Abstract
Background: Multidisciplinary care is pivotal in cancer centres and the interaction of
all cancer disease specialists in decision making processes is state-of-the-art.
Aim: To describe differences of MDTMs by tumour type.
Methods: Twelve multidisciplinary team meetings (MDTMs) with participation of different
cancer disease specialists at a tertiary hospital were assessed by an exploratory sequential
mixed method approach with interviews, observations and a survey to address the follow-
ing five topics: organisational structure and supporting technology; leadership; teamwork;
decision-making, perceived value and motivation. Thirteen persons with different tumour
specialities and levels of seniority were interviewed. The 12 MDTMs were observed twice
by uninvolved persons and evaluated by the participating physicians with a survey.
Results: There were no systematic differences between MDTMs for different tumour
types with the exception of the non-disease specific type MDTM, which was the only
one for which the organisational structure was not driven by an electronic tool. How-
ever, several factors could be identified that generally influenced the functioning of
the MDTMs. In particular, the quality of decision-making was highly dependent on
the availability of case-based information and the presence of relevant cancer disease
specialists. Leadership and teamwork were rated as important and were comparable
across the MDTM. Team participants' motivation and perceived value of MDTMs
was high across all meetings.
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Conclusion: MDTM at a single institution did not demonstrate disease specific char-
acteristics. An effective MDTM, irrespective of the tumour type, can be successfully
structured by technical means and a chairperson coordinating the interaction of can-
cer disease specialists to improve the decision-making process.
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1 | BACKGROUND
Multidisciplinary team meetings (MDTMs); otherwise termed tumour
boards or cancer conferences) are a key element for care planning by
cancer disease specialists at cancer centres internationally.1,2 Such
teams typically include surgeons, oncologists, radio-oncologists, pathol-
ogists and radiologists (and in some settings cancer nurses) involved in
the case-based discussion of a cancer patient and decision making
about their care. The underlying premise of MDTMs is to facilitate
cross-speciality collaboration and to elicit a multidisciplinary expert
review of a patient's tumour and condition, which would not be avail-
able through a single cancer specialist. This multidisciplinary aspect of
cancer care is well recognised and was recently underlined by an initia-
tive of European representatives of cancer disease specialists.3 The
MDTM is therefore the main vehicle for the elicitation of expert clinical
opinions on recommended patient care; and for the integration of these
opinions into the decision-making process for each patient.
As observed in other areas of healthcare delivery,4 the task of aMDTM
of coordinating several cancer disease specialists within the multiple treat-
ment options for an individual patient is complex and can be a challenge.5,6
Cancer treatment processesmanaged by teams are subject to several inter-
nal and external influences.7 Collaboration and teamwork are increasingly
recognised as central aspects of a successful cancer patient care.8 In the
wider healthcare literature, the argument has been consistently made over
the past decade that team functioning can be improved through analysis of
a team, identification of any deficits and implementation of interven-
tions.9,10 How to specifically support the way cancer MDTMs function,
however, remains less well understood. While there is a plethora of
research on decision-making in organisations and teams11 in medical
institutions,2,12 literature on teamwork and leadership in cancer MDTMs
and its implications for patient care is only beginning to emerge.13,14 This
research has started to demonstrate that factors enablingMDTMdecision-
making are defined by both objective parameters and subjective factors.
Objective parameters include facets such as availability of radiology and
pathology reports and the presence of all required cancer disease specialists
at the MDTM. Subjective factors include aspects of team working such as
the quality of team members' contributions to case reviews during meet-
ings, and the team leaders' inputs.15,16
One of the questions that to-date remains debatable is whether
MDTM-working is broadly determined by the same human and
organisational factors across all tumour types, or in contrast, whether
successful MDTM-working modes are tumour-specific. Evidence on this
is very limited. A national self-report survey study from the UK analysed
data collected in 2009 on MDTM-working across different tumour types.
The study revealed that MDTMs in the UK were largely in agreement
regarding their set up.17 However, there were some significant cross-
tumour differences in a few areas, including meeting preparation, selec-
tion of patients for MDTM review, and the overall perceived usefulness
of the team inputs into the decision-making. Further, this study revealed
that haematology team members responded significantly differently
compared to solid tumour experts. We are not aware of any further
studies addressing specifically this question, which is important from the
perspective of infrastructure setup and support offered to cancer teams
in large cancer centres globally. This is an important evidence gap, which
needs addressing before we consider potential team support or training
interventions for cancer teams and MDTMs.
This study aimed to start addressing this gap by evaluating all
MDTMs at a cancer centre in Switzerland. Our primary objective was
to determine whether the studied MDTMs differed by tumour type
regarding their supporting organisational and technological structures,
leadership, and a wide range of human factors – including quality of
team working, decision making and perceived value of the MDTM to
cancer care. Our secondary objective was to add to the evidence base
on MDTM organisation and support. In doing so, we aimed to produce
evidence to inform Swiss cancer policy, as there is currently no formal
guidance regarding how to structure and organise cancer teams in
Switzerland.
2 | METHODS
2.1 | Study design and setting
This was a descriptive mixed-method study, which used an explor-
atory sequential design including a number of data collection
techniques to collect qualitative and quantitative data on MDTM-
working.18,19 The study was conducted at a single institution of a
tertiary hospital in Switzerland. The study was reviewed and approved
as a quality of care evaluation by the relevant hospital board; and all
participants consented to the study data collection procedures
(described below) prior to the data collection.
2.2 | Study sampling framework and procedure
At the time of study conduct, 12 MDTMs for different tumours were
established at the hospital. All of these teams and the staff attending
the MDTMs represented the study population and were eligible for
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inclusion in the study (see section 2.3 for details of the sampling done
for the different study phases/methods).
The study was carried out in multiple phases including a charac-
terisation of MDTMs and their practices, exploratory interviews with
individual team members, real-time observations of MDTMs, and a
self-report survey for all MDTM members. To address the primary
objective, the types of data collected through the different methods
are summarised according to the five main topics of interest (Table 1).
2.3 | Data collection
2.3.1 | MDTM characterisation
The main characteristics of MDTM including organisational structure
and procedures in place (e.g., type of IT support, meeting frequency
and leadership etc.) were collected by the first author (FH) for each of
the hospitals' MDTM based on current daily practice. These aspects
of MDTM-working can impact on the team interactions, hence were
collated for a subsequent synthesis of the findings.
2.3.2 | Interviews with team-members
The exploratory interviews aimed at obtaining detailed information on
the functioning of the teams from individual MDTM members and to
develop a better understanding of the complex social processes and
potentially controversial issues around MDTMs in order to inform the
content of the quantitative survey. The semi-structured interviews
were based on an existing interview guide used with UK cancer
MDTMs and adapted for the purpose of this study.20 Key questions
addressed participants' opinions on MDTM attendance/role as partici-
pant, information presentation, case discussion, leadership, decision-
making process, facilitators/barriers to effective team working, the
motivation to participate and the value of the MDTM including their
educational benefit (Table 1).
Interviewees were sampled purposefully to ensure representation
across different specialties and hierarchy levels. Thirteen interviews
with 10 heads of department/consultants and three trainees were
conducted face-to-face covering the following specialties: pathology
(N = 1), radio-oncology (N = 1), surgery (N = 3), oncology (N = 3),
radiology (N = 1), haematology (N = 1), neurology (N = 1), dermatol-
ogy (N = 1) and gynaecology (N = 1). An interviewer experienced in
conducting semi-structured interviews (KR), who was not a member
of any of the MDTMs conducted the interviews. Oral consent was
given by the interviewees before the recording started. Each inter-
view lasted between 30 and 45 min; all interviews were audiotaped
and transcribed verbatim. Each transcript was analysed by two
researchers independently using standard recommended analytic
techniques.21 In brief, the coding was thematically guided by the
interview questions and complemented with an inductive thematic
analysis. In addition, one of the researchers (MK) specifically searched
for phenomena and processes known from research on decision mak-
ing in groups,22 multi-disciplinary team23 and communication culture
in organisations,24 which may be implicitly expressed by interview
participants. The identified themes were discussed among all authors
to decide how they would subsequently be used to inform the con-
tent of the study survey. Verbatim quotes were extracted from the
interviews to illustrate the identified themes.
2.3.3 | Real-time MDTM observations
For the real-time team observation during MDTM two assessment
tools were applied, the Metric for the Observation of Decision-making
(MDT-MODe)20,25 and the ATLAS tool.26 The MDT-MODe has been
developed specifically to assess cancer teams' interactions in real-time
and was validated for use across several tumour types. It allows a
quantitative assessment of patient and disease related information
discussed during the MDTM (patient history, imaging, pathology,
comorbidity, psycho-social information, patient knowledge by the pre-
senting physician) and also assesses the level of team working during
a case review. The validated ATLAS tool has been developed to assess
elements of team leadership in the context of cancer care with
12 chairing criteria (Table 1).
We trained 12 observers, six with a clinical and six with a non-
clinical background. All of the observers have never participated in
MDTMs before. The tools were translated into German using
forward-backward translation. The training included explanation of
the tools content and how to apply them supported by illustrative
videos of good and poor teamwork behaviours in cancer MDTMs.
EachMDTMwas subsequently observed once by a pair of observers
(one with, one without clinical background) who were present
during the meeting. The different criteria included in the MDT-
MODe and ATLAS were rated based on verbal descriptions of
behaviours on three levels corresponding to 1 = poor, 3 = average,
and 5= excellent.
Observations were analysed descriptively (means and standard
deviations) for each criterion and according to MDTM. If available, we
first calculated the mean of the two observers for each patient. If one
observer had been unable to provide a rating for a specific element
included in MDT-MODe or ATLAS, we included the single rating in
the analysis. Means and standard deviations were calculated for each
element scored. We also descriptively analysed the MDTM treatment
decision taken for each patient (decision taken; decision suspended;
or observers did not agree).
2.3.4 | Team-members survey
The self-report MDTM-members' survey was developed based on the
themes identified in the interviews (Table 1). The survey included
items addressing teamwork (six items), leadership (five items) and
decision-making (two items) in MDTMs. Participants were asked to
rate if they agree with each statement on a scale ranging from
1 = not at all to 7 = absolutely. We further assessed motivation for
participation in the meeting (single item, with eight response options)
and perceived value of the MDTM a participant had just attended
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TABLE 1 Topics addressed within the interview, observation and survey by qualitative and quantitative methods





• Who is participating?
• What information is
presented and how do you
rate the quality of it?
• Is there a case selection?








• patient known by the presenting
physician
• Type of MDTM meeting just attended
• Participants position (hierarchy levels)
• Participants specialty
2 Leadership • What constitutes ideal
leadership for you?
• What do you like/dislike
about the way the meeting
is led?
• What behaviour do you





• Chairing by enhancing team work
and decision making
• Facilitate the discussion/listening
and communicating
• Ability to summarise cases using
information that emerged during
MDTM and formulate a decision
• Keeping meeting focused
• Management of disruptive
personalities and/or conflicts
• Allowing/encouraging all team
members to contribute
• Creating a good working atmosphere
• Prioritisation of cases is adequate
• Time management and quality of decision
is in equilibrium
• Divergent opinions are included in the
discussion
• Discussion of controversies is avoided
• Own contribution to patient case
discussion is appreciated by leader
• Decision based on best qualified person,
irrespective of hierarchic level
3 Team work • How is the quality of the
discussion among meeting
participants?
• How is the atmosphere
during the discussions




• team contribution • MDTM atmosphere is open to discussion
sensitive topics and controversies
• The way of interaction among participants
enables decision-making
• Own competencies are asked from
colleagues
• The board is open for criticis
• The final decision is based on consensus
among participants
4 Decision making • Is always a decision taken?
• Is there a protocol of the
decision?
• What is needed to improve
the decision making process?
• Decision taken (yes, no, deferred to
next MDTM)
• Each patient discussed has a clear
treatment plan
• The final decision is based on consensus
among participants
• Decision-making is based on expertise




• How do you rate the MDTM
regarding its structure and
effectiveness'
• What do you like/dislike
about the MDTM?
• Do you think that MDTM
have an educational benefit?
• Do you have time to
participate?
• What is your role at the MTC
meeting
• Do you think you can
perform your role as
expected?
Not applicable One question addressing the perceived value
of MDTM with seven response options:
• better diagnostic and therapeutic
decisions
• coordination of patient care
• furthers the safety of the therapy
• securing the influence of my/our
discipline
• exchange of information between
participting disciplines
• continued training of the attendees
• the observance of the regulations of
certification
One question addressing the motivation for
participation with eight response options:
• need of diagnostic or therapeutic decision
for patient
• collegiality
• others benefit of my knowledge
• time available today
• help for decision-making
• educational benefit
• substitute for colleague
• obligation
Note: Observation: A 1–5 scale to evaluate was used, being 5 the best answer on the scale with the following interpretation: high (4–5); moderate (2–3);
low (0–1). Survey: Rating of 1–7 of a Likert scale was used.
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(single item, with seven response options). The questionnaire was
pilot tested with regard to feasibility and comprehension prior to data
collection. Data collection took place once at the end of each
meeting. Each survey question was analysed individually, with
responses to each question summarised descriptively (means and
standard deviations) and according to MDTM. There was no formal
statistical testing of differences observed between MDTMs – as
we did not have any such hypothesis to formally evaluate. The
study was therefore not designed or powered to evaluate cross-
MDTMs differences.
In the final stage of the study, all data from the different sources
were reviewed synthesised in order to produce a global assessment of
MDTM working across tumour types.
3 | RESULTS
3.1 | Characteristics of MDTM's
Table 2 gives an overview of the 12 assessed MDTMs with respect
to the meeting frequency, use of an electronic database, team lead-
ership/chairing, focus of decision-making, average number of
attendees and their specialties. The MDTMs at the study site typi-
cally worked as follows: registration of patients to be reviewed was
carried out in advance. Patient case registration was based on a
common electronic database, to which all physicians had access.
The database structured the patient case information for the stage
of the tumour and the information needed from the MDTM mem-
bers. At the meetings, patient cases were presented by the treating
physicians, followed by a review of case-based imaging and pathol-
ogy reports. The decisions were based on clinical/scientific consid-
erations and were not designed to include patients' preferences at
the time of the MDTM – though these preferences were expected
to be taken into account when the patient saw his/her treating phy-
sician subsequently to the MDTM. MDTM attendees and decisions
for all reviewed patient cases were recorded. Case discussions were
focused on both diagnostic and therapeutic decisions within the
same MDTM, except for the breast MDTM, which was divided in
two meetings: a diagnostic (pre-operative) and a therapeutic (post-
operative) MDTM. The 12 MDTMs usually lasted between 30 and
45 min and were attended by a total of 183 physicians of different
specialties involved in cancer care with different levels of seniority
(Table 2). Cancer nurses or patients did not attend the MDTMs.
Some differences between the setup of MDTMs were also
identified. The breast, gynaecological and gastrointestinal MDTMs
had a predefined chairperson who led the team through the discus-
sion of the different cases and predefined standard procedures for
the typically presenting cases. These three MDTMs also included
participants from external collaborating hospitals by real-time via
videoconference. For the remaining MDTMs, there was no clearly
identified chairperson to lead the discussion. Further, the single
non-disease specific MDTM had no patient registration in advance
of the meeting.
3.2 | Exploratory interviews with team-members
Individual interviews revealed that participants of MDTMs were pre-
pared for their case presentation. The standardisation of information
presentation and the prioritisation of cases based on their complexity
were factors seen as contributing to the efficiency of MDTMs:
The diagnosis is shown, the underlying disease, secondary
diseases. Histology, images, - X-rays, CT images, MRI's
are presented. Everything that is done in terms of exami-
nation and diagnostics for this case is discussed together
and interactively (I13, head of department)
Interview participants considered the chairperson's ability to structure
the discussion, prioritise cases, control time management, value indi-
vidual opinions and leading through controversial discussions as
important attributes of effective team leadership:
Someone who bundles all the information that is being
discussed and then makes the final decision and says: This
is how we're going to do it now. But everyone has to
agree (I3 trainee).
They also considered the expertise of each participant an important
feature to successful MDTMs, but indicated that the meeting should
not be dominated by opinionated individuals:
The tumour board is only as good as the individuals who are
on it. The more experience they have, the better the profes-
sional quality of the decisions (I2, head of department).
Problematic issues in MDTMs included hidden conflicts between
chairperson and disease experts, unprepared experts, and case pre-
sentations that were inserted into the meeting late (hence lack of
preparation for them) or had missing information.
Interview participantsmentioned the ability to reach consensus, good
camaraderie within the team, a psychologically safe atmosphere and a
constructive culture of debate as facilitators for effective teamworking:
One is allowed to speak freely and is not somehow cut off or 'Be
quiet now'. Yes, it is actually a discussion with each other. At
least in this tumour board it is a ‘with each other’ (I3 trainee).
In contrast, barriers identified by the interview participants included
power struggles between specialities, the imposition of clinical opin-
ions by individuals, different views on who is qualified to take a deci-
sion and decision-making occurring outside of the MDTM:
The different points of view are problematic, or: Who has sov-
ereignty over patients? The surgeon thinks differently than the
oncologist or the gastroenterologist. And sometimes narcissis-
tic personality structures come into play, which then make the
decision no longer objective (I6, Head of department).
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All interview participants shared the opinion that the attendance of
cancer disease specialists from different disciplines is necessary for
successful decision-making, but they also indicated that it might be a
platform for demonstrating individual power:
Now and then because of political infighting - so to speak
– the meetings take a bit long. It becomes more of a
power show than really patient-centered (I7, Head of
department).
Lastly, MDTMs were seen as a forum for clinical education. However,
the motivation to participate was reported to be sometimes hampered
by lack of time or conflicting clinical priorities:
The potential for education is very high, but there are far
too few trainees attending the meetings (I8, Head of
department).
3.3 | External observers' ratings of MDTM
The observer analysed 153 patient cases, with a minimum of four and
a maximum of 36 patient cases per MDTM and 8–72 observations,
respectively. Ratings from both observers were available for 137 of
these patient cases. MDT-MODe was the tool used to score patient
discussions.
The ratings for patient and disease related information regarding
patient history and patient being known by the presenting physician
resulted in high mean scores. Imaging was always present, whereas
pathology reports were presented with large variation across the
MDTMs. The discussion of psycho-social information and patient's
preferences were scored low in all of the observed meetings (Table 3).
The observations of experts' contribution from and radiology rev-
ealed largely divergent results for different MDTMs. Most striking
was the result for soft tissue and sarcoma MDTM with excellent
scores (mean ratings above three) for the contribution of radiologists
and pathologists. Other MDTMs with presence of these disciplines
scored lower (mean rating 1.5 for gastrointestinal neoplasm MDTM)
but reached a mean score above three for radiologists.
In 125 (82%) patient cases in the observed MDTMs a clinical
treatment decision was reached. Suspended decision (unclear or miss-
ing) were reported in 10 cases (7%). Six out of 10 cases (7%) with
suspended decisions were in the non-disease-specific MDTM. In
119 of 137 cases with two observations the observers were in agree-
ment on whether a decision was taken or not (Tables 3 and 4).
The observers also used ATLAS to score leadership in the
observed MDTMs. The total score for leadership based on the mean
rating of the predefined nine categories of the validated observation
tool (ATLAS) was good (mean scores 4–5) in five MDTMs and moder-
ate (mean scores 2–3.9) in the remaining seven MDTMs. Prioritisation
of complex and urgent patient cases was scored overall low across
MDTMs (mean scores 0–1.9).
TABLE 2 Characteristics of studied MDTMs and participants
Multidisciplinary teams













Twice weekly Present explicit Therapeutic > diagnostic 20 a
2 Thoracic malignancy weekly Present explicit Therapeutic > diagnostic 15 a
3 Central nervous system
malignancy
weekly Present implicit Therapeutic > diagnostic 6 b
4 Urologic malignancy weekly Present implicit Therapeutic > diagnostic 8 b





weekly Absent implicit Therapeutic > diagnostic 10 c
7 Breast pre-operative weekly Present explicit Diagnostic >
Therapeutic
10 a
8 Breast post-operative weekly Present explicit Therapeutic > diagnostic 10 a
9 Gynaecologic malignancy weekly Present explicit Therapeutic > diagnostic 15 a
10 Ear-nose-throat
malignancy
weekly Present implicit Therapeutic > diagnostic 20 a
11 Soft tissue and bone
malignancy
Fortnightly Present implicit Therapeutic > diagnostic 10 a
12 Dermatologic malignancy monthly Present implicit Therapeutic > diagnostic 6 b
Note: a – participation of surgeon, medical oncologist, radio-oncologist, radiologist, pathologist. b – participation of surgeon, medical oncologist, disease
related specialist as neurologist, dermatologist, haematologist. c – participation of surgeon, medical oncologist; no presence of radiologist, no pathologist.
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3.3.1 | Survey results
Of the available population of 183 team-members in attendance of
the meetings, we received 181 surveys (response rate = 99%).
The survey participation reflects a typical constitution of MDTM:
Seniority levels were represented with 8% heads of department, 32%
senior consultants, 30% junior consultants and 30% trainee physi-
cians. Participants' specialties were as follows: 40 medical oncologists,
79 surgeons, 10 radio-oncologists, nine gastroenterologists, four
haematologists, three neurologists, and two dermatologists, laboratory
experts included nine radiologists, and 10 pathologists.
Several of the leadership facets mentioned in the interviews were
rated quite positively by the MDTM participants (Figure 1). Case
prioritisation (mean 4.9; SD 1.7) and time management received high
ratings (mean 5.1; SD 1.6), both showing scores above four. Similar
high ratings were given to items focused on divergent opinions are
included in the discussion (mean 5.4; SD 1.2) and decisions based on the
most qualified person irrespective of the hierarchic position (mean 5.6;
SD 1.1). These results were similar across MDTMs. Only in the
MDTM for pre-operative breast cancer that is exclusively diagnostic
the ratings for time management and prioritisation were higher (mean
6.1; SD 0.9). The four questions in the survey that addressed overall
teamwork competencies were rated on average between 4.9 and
maximal 6.0 (range 1–7 Likert scale) (Figure 2). We were not able to
detect meaningful differences of teamwork ratings between the diag-
nostic (pre-operative) and therapeutic (post-operative) breast MDTM.
The survey responses indicated a considerable uniformity across all
MDTM with respect to decision making: final decision is based on con-
sensus among participants (n = 177; mean value 5.4, SD 1.3); decision-
making is based on expertise independent of position or hierarchy of opin-
ion leaders (n = 173, mean value 5.6, SD 1.1) and the way of interaction
among participants enables decision-making (mean 6.0, SD 0.9).
Figure 3 displays the perceived value of MDTM: Taking better diag-
nostic and therapeutic decisions, was valued by the participants as the most
important contribution of an MDTM. This priority was also seen compar-
ing the disease-specific MDTMs, the expertise levels and specialities.
However, there were some differences seen between experts for
several responses: Medical oncologists chose taking better diagnostic and
TABLE 3 Observer ratings for patient and disease related information in means and standard deviation
Type of information Decision taken (n = 125)
Decision
suspended (n = 10)
Observers did not
agree (n = 18)
Patient history 4.8 ± 0.6 4.2 ± 0.9 4.8 ± 0.5
Imaging 3.8 ± 1.7 2.8 ± 2.0 2.8 ± 1.9
Pathology 2.4 ± 1.3 2.5 ± 1.2 2.2 ± 1.0
Psycho-social information 1.6 ± 1.0 1.9 ± 1.2 1.5 ± 1.1
Comorbidity 2.1 ± 1.3 1.4 ± 1.0 1.2 ± 0.6
Patient's views represented by the physician 1.6 ± 1.1 1.0 ± 0.0 1.4 ± 0.8
Patient seen by the presenting physician 4.7 ± 0.5 4.7 ± 0.8 4.5 ± 0.8
TABLE 4 Agreement between observers* regarding the decision taken






not agree (n) Total (n)
1 Gastrointestinal malignancy 33 0 3 36
2 Thoracic malignancy 12 0 2 14
3 Central nervous system malignancy 8 1 1 10
4 Urologic malignancy 11 0 0 11
5 Haematology 4 1 1 6
6 Non-disease specific board 10 6 0 16
7 Breast pre-operative 4 0 0 4
8 Breast post-operative 5 0 0 5
9 Gynaecologic malignancy 14 0 6 20
10 Ear-nose-throat malignancy 10 2 3 15
11 Soft tissue and bone malignancy 8 0 2 10
12 Dermatologic malignancy 6 0 0 6
Total 125 10 18 153
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therapeutic decision more often than surgeons (n = 40; 87% vs. n = 79;
76%). Likewise, coordination of patient care was also more often chosen by
medical oncologists than surgeons (n = 40; 62.5% vs. n = 79; 47%).
The question addressing the motivation for participation was
answered by only 40/183 participants. The most obvious motivation
for participation was the need of a diagnostic or therapeutic decision
(30%), followed by a commitment to sustain the decision-making pro-
cess with personal knowledge and expertise (25%). Motivations
appeared to differ across MDTMs. The most striking difference was
seen for the visceral surgery MDTM with a much higher number of
responses for a commitment to bring in expertise (50%); whereas in
postoperative breast tumour the motivation for a diagnostic or thera-
peutic decision was highest (66%). Across levels of expertise, trainees
stated they were typically attending a meeting with the aim to reach a
treatment decision by the team, whereas this was least mentioned by
senior heads of departments.
Lastly, an educational benefit was expressed overall by 17.5% of
the participants. Analysis based on level of expertise/hierarchy
F IGURE 1 Survey leadership issues
F IGURE 2 Survey teamwork competencies
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indicated that trainees (39%) valued educational benefits higher than
junior consultants (20%). Heads of department and senior consultants
reported no educational value of the meetings.
3.4 | Discussion
Our study met both of its objectives. Using multiple methods and
sources of data, we were able to characterise in detail the struc-
ture and functioning of all MDTMs within the study hospital –
thereby offering the first such detailed description of a cancer
centre within the Swiss cancer care system. We identified
areas where the participants who attend these meetings agree on
what ‘works’ and also on where problems may arise. We also
established areas where clinical information needed by the teams
reviewing the patients; infrastructure support; and team proce-
dures are available and facilitate the decision-making process27;
and other areas that seem to be lacking. Lastly, we were able to
produce a detailed analysis for a Swiss cancer centre that is
directly comparable on how cancer teams work and how they can
be supported. Overall, we studied descriptively 12MDTMs within a sin-
gle Swiss cancer centre and did not observe obvious differences in the
organisational and team working facets across them. Our findings are
largely in line with the UK study that surveyed MDTM members across
different tumour types and found a largely homogeneous pattern of
responses with regards to their set up and team functioning.17 From
the perspective of cancer care andworkforce planning, this is a notewor-
thy finding. It suggests that policies can largely be applied across
MDTMs – provided they address effectively the key parameters of
MDTM working within the specific context, as captured for the Swiss
context in this study.
In the most recent systematic review of team working in cancer
teams that we are aware of, Horlait et al.8 reviewed 49 studies carried
out across 12 countries. The review offers a framework for consider-
ing the evidence base on team working in MDTMs – which includes
structural characteristics (of MDTMs, hospitals and healthcare sys-
tems), leadership, participation and involvement, and organisational
culture. Of these, our study offers insights into the first three. We
apply the framework outlined by this review to organise our interpre-
tation of our findings and recommendations.
First on structural characteristics, our study demonstrates the
overall beneficial role of clear and supportive structures for
the MDTM. The electronic registry of patients was used by all teams,
except one and was found to contribute to a straightforward case dis-
cussion within an MDTM irrespective of the disease. Electronic regis-
tration tools can support and improve the organisation of MDTMs,
which appeared to also be the case in our study.28 The further poten-
tial of clinical decision support technology in MDTMs for assistance,
preparation, data collection and documentation of decision is well
documented.29 Further to the technology, we also found that some
MDTMs had an established and clearly defined chairperson – which
again was seen as facilitative of the overall case review and an active
coordinator of the meeting flow. In light of these findings it follows
that IT support is part of the infrastructure host a hospital should pro-
vide for the cancer teams. Also, within the teams, a designated chair-
person is needed.
Second on leadership, we observed that who chaired the MDTMs
was typically defined by the hierarchy of the experts in attendance,
such that chairing was typically undertaken by the moist senior person
present. Anecdotally, this is not an uncommon practice (in healthcare
meetings overall, we believe). In this study, the views of MDTM mem-
bers in the survey were very positive, and this pattern was confirmed
by high scores on the observational assessment of leadership during
the meetings. The emerging picture is that, in the centre we studied,
leadership of MDTMs seemed to be well-applied and received. We
are unable to comment on whether an alternative model to team lead-
ership might work better, as such a comparison was not available. A
recent study revealed that, in naturally occurring cancer MDTMs, in
which experts took turns to speak during the meeting, the pace of
speech was very fast, such that the natural pauses (i.e., opportunities
to speak) were few.30 The risk this presents for a fast-paced MDTM is
that the conversation might be dominated by some vocal individuals –
a risk that we noted in our interview analyses in this study too. These
findings suggest that the role of the chairperson in ensuring the meet-
ing is truly one of multiple voices is critical – and this role might not
depend on clinical seniority. We hypothesise here the potential for a
MDTM chairing ‘model’ with a meeting chair selected for their
chairing skills and even perhaps without direct involvement in the care
of the reviewed patients, who concentrates on the process of sharing
information and making decisions.31,32 Chairs of MDTMs can focus
F IGURE 3 Survey perceived
value of all MDTM
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on facilitating case reviews and involve experts into the discussion to
ensure their contribution to the decision-making process.33 We would
propose to our colleagues who regularly attend (and chair) MDTMs to
consider and trial this alternative strategy, and report their experi-
ences with it. Added to this, the evidence suggests that professional
development and support to MDTM current chairs should be offered
by cancer centers to enable them to undertake their role effectively.
Third, on participation and involvement, we obtained an interest-
ing pattern of findings. One observation of note is the systematic
under-representation at the MDTMs of information about the prefer-
ences or comorbidities of the patients under review. This despite the
fact that in the majority of the cases there was a person at the meet-
ing who had personal knowledge of the patient. This finding suggests
that the teams tended to focus on oncological aspects of the tumour,
with less attention paid to the rest of the clinical and psychosocial
aspects of care.34 The fact that cancer nurses did not attend the
MDTMs at that time (they still do not do so in Switzerland) might
offer some explanation for the latter part of the observation. Even in
healthcare systems where nurses do attend the meetings, such as
in the UK, the same lower priority to these facets of care has been
shown in observational studies.35 We believe that this is an area of
potential improvement. Care planning and delivery subsequent to the
MDTM can only be enhanced if the full clinical picture is known about
a patient, so that the MDTM does not waste time considering options
that are clinically not applicable. This can be done using a simple
checklist, prepared ahead of the MDTM.20 Further, pathway analyses
are required to establish at what point of the pathway it is optimal to
discuss with the patient their circumstances and preferences. It could
for example be that the optimal time to do so is after the MDTMs has
arrived at a set of potential recommendations, which will then be
communicated by the treating physician.36 A second observation in
relation to participation and engagement, is the differential motiva-
tions across team-members for attendance and some tensions we dis-
covered. Improved decision-making and care coordination were more
strongly prioritised facets of the MDTMs attendance by oncologists
compared to surgeons. This opens up some questions regarding what
might add more value to these meetings from the surgical perspec-
tive.37 Interestingly, trainees in attendance prioritised having a clinical
decision to implement at the end of the meeting; and educational
objectives were prioritised by overall more junior staff-members. The
integration of teaching elements into tumour MDTMs is reported in
some research, though not well documented.38,39 The value of a
MDTM could be increased by explicitly incorporating continuous
medical education (incl. in available clinical trials) and promoting multi-
disciplinary learning even for experienced attendees.40 More studies
are needed in how educational approaches can be optimised within
cancer MDTMs.
3.5 | Strengths and limitations
The study has several strengths. We chose to combine qualitative and
quantitative methods to reflect both an external view on an MDTM
(MDTMs characterisation and observation methods) and an internal
view with information coming directly from team-members (interview
and survey methods). We applied validated observational tools (MDT-
MODe and ATLAS) specifically designed for MDTMs and applied by
trained observers, which overall worked well in the Swiss clinical
setting. The joint application of these methods and analysis of the
findings allowed us to produce a comprehensive picture of the studied
MDTMs.
Limitations included that the study was carried out at a single
institution, hence we cannot be certain to what extent the findings
reflect an institutional perspective. The generalizability of our obser-
vations to other Swiss cancer centres or elsewhere remains to be
tested through multi-institutional studies. Moreover, due to the purely
descriptive nature of the study, we are not able to comment on how
well the MDTMs studied performed in relation to an external perfor-
mance benchmark. Furthermore, we took a sampling approach that
maximised breadth, which means we analysed a wide range of cases
and numbers of participants across the different MDTMs; this limits
our ability for cross-group or tumour-specific statistical comparisons
due to small subgroup samples sizes. Methodologically, we report
findings descriptively as the study was not designed, or powered, to
evaluate specific inter-group differences. We did not carry out
member-checking as part of the interview analysis or a peer-
debriefing as part of the observational data analysis. Lastly, the cross-
sectional nature of the study at a single time point meant a limited
sampling window, so we cannot account for the contribution to team
functioning of different leaders, experts and caseloads over time. The
final results of the MDTM study will be presented to the participants
for further development and improvement of the structure and team
interaction.
3.6 | Future directions
To our knowledge this is the first descriptive study addressing in
depth the issue of MDTM working practices across numerous tumour
types and the first study of this types in Switzerland. Overall, we
found a coherent pattern, suggesting that policies and guidelines to
support MDT functioning sufficiently address the needs and ways of
working of all types of MDTMs in Swiss cancer centres. This study is
largely replicating a pattern found in MDTMs globally.8 From a
research perspective the tools that this study applied, can be used to
carry out comparative analyses between cancer centres in Switzerland
and beyond.41 From a practice perspective, the tools used to charac-
terise MDTMs may also be useful for cancer teams to analyse their
own work patterns and identify opportunities for improvement – for
example, through the formal appointment of a skilled MDTM chair-
person to facilitate the case reviews. The analysis of the MDTM's that
we have carried out can be fed directly into practical recommen-
dations for MDTMs to implement locally. We have articulated
some of these already – including a defined chairperson, and con-
sideration of allocating the role without reference to clinical
seniority. A simple checklist can be used to work up cases prior to
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MDTM presentation and hence improve the information coverage
of clinical comorbidities. From a hospital perspective, offering consis-
tent IT support and professional training in meeting chairing and lead-
ership skills are areas the hospitals should invest in to support their
cancer teams. Lastly, further consideration should be given to informa-
tion about the patient's circumstances and wishes – understanding of
the flow of the cancer pathway is needed to identify where this can
be done best. We hope that the study offers a baseline for both
discussions with health policy makers about advancing the delivery of
cancer care in Switzerland and for improvements to be considered to
improve routine daily practice in cancer care.42
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